Shopping Cart
- Remove All
Your shopping cart is currently empty
Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $668 | 1-2 weeks | |
| 50 mg | $868 | 1-2 weeks | |
| 100 mg | $1,310 | 1-2 weeks |
| Description | Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. |
| Targets&IC50 | PKCε:600 nM, PKCδ:250 nM, PKCβII:5.9 nM, PKCη:52 nM, PKCα:360 nM, PKCγ:300 nM, PKCβI:4.7 nM |
| Synonyms | LY-333531 Mesylate, LY-333531, LY333531, LY 333531 |
| Molecular Weight | 564.65 |
| Formula | C29H32N4O6S |
| Cas No. | 192050-59-2 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.